



LKT Laboratories, Inc.

IPI-549

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID I611325

CAS No. 1693758-51-8

Chemical Name IPI-549

Synonym IPI 549, IPI549

Formula $C_{30}H_{24}N_8O_2$

Formula Wt. 528.58

Melting Point


Purity $\geq 98\%$

Solubility

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description IPI-549 is a selective inhibitor of the γ isoform of PI3K (PI3K γ). It is being investigated along with nivolumab, an immune checkpoint inhibitor, as an immuno-oncology treatment for advanced solid tumors. IPI-549 reprograms macrophages to an immune-activating phenotype in preclinical studies.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
I611325	5 mg	\$123.40
I611325	25 mg	\$292.10
I611325	100 mg	\$843.60

References Evans C., Liu T., et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)- γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. *ACS Med Chem Lett.* 7(9):862-7 (2016). PMID: 27660692.

De Vera A., Gupta P., et al. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. *Cancer Lett.* 442:91-103 (2019). PMID: 30391357.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.